PHILADELPHA, Dec. 20, 2011 /PRNewswire/ -- Premier Research Group Limited announces the appointment of Hua Gong to the position of Executive Director of Medical Diagnostics. In this role, Dr. Gong will be responsible for overseeing the In Vitro Diagnostics (IVD) business within the company.
Dr. Gong brings more than 12 years of experience that includes both R&D and clinical expertise in the development of diagnostics. Her past operational experience within both large and small pharmaceutical companies provides Premier Research with a strong skill set to assist diagnostic companies with product development, regulatory expertise, and clinical trial management.
Prior to joining Premier Research, Dr. Gong was the Associate Director, Medical Diagnostics at Prometheus Therapeutics & Diagnostics where she was responsible for leading the development of companion diagnostics for pharmaceutical companies, overseeing multiple clinical studies to validate their oncology platform as well as contributed to their CEER HER2 510K submission. Additionally, she worked at Pfizer for 10 years in a variety of positions of increasing responsibility. In her last position at Pfizer, Dr. Gong served as Principal Scientist, Oncology Exploratory Biology where she managed a multi-disciplinary team including intro/vivo biology, PDM, drug safety and biomarker research groups.
Dr. Gong received a medical degree in preventive medicine from An Hui Medical University in China, a doctorate in cancer biology from Wayne State University in the United States, and a master of sciences in biostatistics from Sun-Yet-Sen University of Medical Sciences. She has authored more than 15 publications and presentations with a recent focus in oncology and biomarkers.
Bernard Sweeney Vice President, Medical Devices commented, "Hua brings extensive, relevant experience in this fast expanding area having worked with in both the development and commercial sectors of the IVD industry. This business is unique within healthcare and is presently experiencing global changes from regulatory decision makers. It also reflects the move within healthcare to evaluate patient needs and progress through treatment to improve patient outcomes. Together these factors mean that it is necessary for the service provider to be able to meet the specific needs with dedicated resources."
About Premier Research
Premier Research is a professional services company providing clinical development support to the pharmaceutical, biotechnology, and medical device industries. Founded in 1989 and headquartered in Philadelphia, USA, the company currently has 21 offices across North America and Europe and operates in over 30 countries worldwide. The company is a leader in performing clinical research in the analgesia, oncology, pediatrics, medical device and neurosciences areas. Additionally, it has grown a strong strategic sourcing group that supports customers in their resource planning and management.
The company offers a comprehensive series of services for every phase of clinical development including, regulatory affairs, clinical trial management, medical affairs and strategic consulting, pharmacovigilance, data operations, biostatistics, medical writing, interactive response technologies, and quality assurance.
For more information please visit, www.premier-research.com.
SOURCE Premier Research Group Limited